Seattle, WA - (WORLD STOCK WIRE) - March 9, 2012 — VentriPoint Diagnostics Ltd. (TSXV: VPT) a medical device company engaged in the development of diagnostic tools, using patented technology licensed from the University of Washington, for monitoring patients with heart disease will present today at the Southern California Investment Forum in Newport Beach, California.
More information can be found at http://www.southerncaliforniainvestmentforum.com/
Mr. Alan Stone, Managing Director of WallStreet Research™ and event organizer commented: “We are pleased to continue our prominent SCIF series of investor meetings. We have lined up several newly discovered companies, including Ironclad VentriPoint Diagnostics Ltd. (TSXV: VPT)”.
Mr. Stone continued: “Sponsored by Brentwood News, Westside Today and Crown Equity Holdings (OTCBB: CRWE), our event is gaining wide media recognition in Southern California, resulting in CEO interviews by Jeff Hall, a publisher of several local community newspapers, as well as other media coverage. In addition, Crown Equity Holdings is providing various media and advertising services including selected CEO interviews and video shoots at the event.
The Southern California Investment Forum is a part of ongoing nationwide road show and conference activities organized by WallStreet Research™, an affiliate of Alan Stone & Company, LLC. The firm has been active on the West Coast for over twenty years, running investor meetings in San Francisco, Los Angeles, Beverly Hills, Newport Beach, San Diego, and Las Vegas with clients listed on NYSE, AMEX, NASDAQ, OTC, TSX and other foreign exchanges. With offices and staff in Los Angeles, San Francisco, New York City, and Palm Beach, FL, WallStreet Research™ is also the host of a prominent annual investor conference held in New York City, with more info at www.SmallCapConference.org
WSR is today ranked NUMBER ONE on the Google, Yahoo, and Bing search engines, and its Small Cap Conferences are also ranked NUMBER ONE on the search engines. For more information please review a recent Opportunist Magazine article at www.opportunistmagazine.com/alan-stone-thinking-small-to-win-big-name
About VentriPoint Diagnostics Ltd.
VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. The VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Monitoring congenital heart disease is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure - a multibillion-dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of VentriPoint’s VMS™ heart analysis system and VentriPoint is pursuing US-FDA approval through the 510(k) process.
VentriPoint Diagnostics Ltd.
100 West Harrison Street
Seattle, WA 98119
Phone: 206) 283-0221
Fax: 206) 283-2309
Note: The following news is from VentriPoint Diagnostics Ltd., and World Stock Wire, Inc. is not liable for the contents of this news.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWENewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWENewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwenewswire.com/disclaimer).
Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.